Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.680,02
1,26%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Processa Pharmaceuticals Inc (PCSA) Processa Pharmaceuticals Inc (PCSA) Notizie

Processa Pharmaceuticals Inc

PCSA
2,14
-0,12 (-5,31%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202414:00GLOBEProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice..
11/4/202414:00GLOBEProcessa Pharmaceuticals Presents Two Abstracts at the AACR..
28/3/202413:15GLOBEProcessa Pharmaceuticals to Present at the MedInvest Biotech..
25/3/202413:15GLOBEProcessa Pharmaceuticals to Present Data at the American..
21/2/202423:25EDGAR2Form 8-K - Current report
21/2/202414:15GLOBEProcessa Pharmaceuticals to Present at the 2024 BIO CEO &..
14/2/202419:00GLOBEProcessa Pharmaceuticals to Present at The Winter Wrap-Up..
06/2/202414:30EDGAR2Form 8-K - Current report
06/2/202414:30GLOBEProcessa Pharmaceuticals Regains Compliance with Nasdaq..
02/2/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:22GLOBEProcessa Pharmaceuticals Announces Closing of $7.0 Million..
31/1/202422:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202416:46EDGAR2Form 8-K - Current report
29/1/202422:15EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
29/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
26/1/202415:04GLOBEProcessa Pharmaceuticals Announces Pricing of $7.0 Million..
25/1/202414:35EDGAR2Form 8-K - Current report
25/1/202414:30GLOBEProcessa Pharmaceuticals Announces Successful Completion of..
19/1/202414:00EDGAR2Form 8-K - Current report
19/1/202413:45GLOBEProcessa Pharmaceuticals Announces Expansion of NGC-Cap..
18/1/202414:30EDGAR2Form 8-K - Current report
18/1/202413:45GLOBEProcessa Pharmaceuticals to Effect a 1-for-20 Reverse Stock..
08/1/202422:30EDGAR2Form 8-K - Current report
02/1/202423:06GLOBEProcessa Pharmaceuticals to Present at the Biotech Showcase..
29/12/202314:55EDGAR2Form S-1 - General form for registration of securities under..
19/12/202315:00EDGAR2Form 8-K - Current report
19/12/202315:00GLOBEProcessa Pharmaceuticals Provides Interim Analysis from..
13/12/202315:00GLOBEProcessa Pharmaceuticals Announces Successful Phase 2..
05/12/202323:18EDGAR2Form 8-K - Current report
30/11/202314:15GLOBEProcessa Pharmaceuticals to Present at the MedInvest..
29/11/202314:15GLOBEProcessa Pharmaceuticals Issues Letter to Shareholders..
16/11/202321:10EDGAR2Form 8-K - Current report
15/11/202317:30EDGAR2Form 8-K - Current report
13/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202320:45EDGAR2Form 8-K - Current report
13/11/202319:40GLOBEProcessa Pharmaceuticals, Inc. Mourns the Sudden Passing of..
09/11/202314:15GLOBEProcessa Pharmaceuticals to Present at the 20th Orphan Drugs..
01/11/202313:15GLOBEProcessa Pharmaceuticals Announces Formation of Oncology..
16/10/202315:15EDGAR2Form 8-K - Current report
13/10/202319:08GLOBEProcessa Pharmaceuticals to Present at the ThinkEquity..
13/10/202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202300:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202300:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202323:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202316:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202316:00EDGAR2Form DEF 14A - Other definitive proxy statements
Apertura: 2,30 Min: 2,15 Max: 2,30
Chiusura: 2,26

La tua Cronologia

NASDAQ
PCSA
Processa Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network